Miller Dave A, DiNunzio James C, Yang Wei, McGinity James W, Williams Robert O
College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, USA.
Pharm Res. 2008 Jun;25(6):1450-9. doi: 10.1007/s11095-008-9543-1.
To investigate the use of Carbopol 974P as a stabilizing agent for supersaturated levels of itraconazole (ITZ) in neutral pH aqueous media and the resultant effects on oral absorption of ITZ.
Carbopol 974P was incorporated into an EUDRAGIT L 100-55 carrier matrix at concentrations of 20% and 40% based on polymer weight with the aim of prolonging supersaturated ITZ release from the enteric matrix. Amorphous solid dispersions of ITZ in EUDRAGIT L 100-55 containing either 20% or 40% Carbopol 974P were produced by hot-melt extrusion (HME). Solid state analysis of these compositions was performed using differential scanning calorimetry and qualitative energy dispersive X-ray spectroscopy. Dissolution analysis was conducted using a pH change method. Oral absorption of ITZ was evaluated in male Sprague-Dawley rats.
Solid state analysis demonstrated that the extruded compositions were entirely amorphous and homogenous with respect to drug distribution in the polymer matrix. Dissolution analysis revealed that the addition of Carbopol 974P to the EUDRAGIT L 100-55 carrier system functioned to prolong the release of supersaturated levels of ITZ from the EUDRAGIT L 100-55 matrix following an acidic-to-neutral pH transition. In vivo evaluation of ITZ absorption revealed that the addition of Carbopol 974P substantially reduced the absorption variability seen with the EUDRAGIT L 100-55 carrier system. In addition, the 20% Carbopol 974P formulation exhibited a five-fold improvement in absorption over our initially reported ITZ particulate dispersion compositions that limited supersaturation of ITZ primarily to the stomach.
The results of this study strongly suggest that substantial improvements in oral antifungal therapy with ITZ can be achieved via intestinal targeting and polymeric stabilization of supersaturation.
研究卡波姆974P作为伊曲康唑(ITZ)在中性pH值水性介质中超饱和水平的稳定剂的用途,以及对ITZ口服吸收的影响。
将卡波姆974P以聚合物重量的20%和40%的浓度掺入Eudragit L 100-55载体基质中,目的是延长超饱和ITZ从肠溶基质中的释放。通过热熔挤出(HME)制备了含有20%或40%卡波姆974P的ITZ在Eudragit L 100-55中的无定形固体分散体。使用差示扫描量热法和定性能量色散X射线光谱法对这些组合物进行固态分析。采用pH变化法进行溶出分析。在雄性Sprague-Dawley大鼠中评估ITZ的口服吸收。
固态分析表明,挤出的组合物在聚合物基质中的药物分布完全无定形且均匀。溶出分析表明,在Eudragit L 100-55载体系统中添加卡波姆974P可在酸性至中性pH转变后延长超饱和水平的ITZ从Eudragit L 100-55基质中的释放。ITZ吸收的体内评估表明,添加卡波姆974P大大降低了Eudragit L 100-55载体系统中观察到的吸收变异性。此外,2%卡波姆974P制剂的吸收比我们最初报道的主要将ITZ过饱和度限制在胃中的ITZ颗粒分散体组合物提高了五倍。
本研究结果强烈表明,通过肠道靶向和超饱和的聚合物稳定化,可以在ITZ口服抗真菌治疗方面取得实质性进展。